Navigation Links
The Burnham buzz

Enzyme May Hold the Key to Muscular Dystrophy

A mutation in the gene coding the protein dystrophin has long been known to be associated with muscular dystrophy, but the role the protein plays in the disease was unknown. Lorenzo Puri, M.D., Ph.D. and colleagues have discovered that the dystrophin mutation causes an increase in the amount of the histone deacetylase enzyme, HDAC2. Increased HDAC2 activity alters the gene expression profile in the diseased muscle cells compared to normal muscle cells. By inhibiting HDAC2 with small molecule compounds or RNA interference, Dr. Lorenzo was able to return the muscle cells with the dystrophin mutation to normal histology and function. This advancement may lead to novel therapies for muscular dystrophy.

Microscopic Race for New Cures

Jeff Price, M.D., Ph.D. has created a next generation robotic microscope which can be used for high-throughput cellular image analysis to discover new potential drugs. The novel instrumentation utilizes chromatic aberrationthe difference in focus between different colors of light in optical systemsto simplify and speed auto-focusing of the microscope via digital color cameras. This advancement will increase screening from the 20,000 -- 40,000 compounds possible per day with existing technology, to more than 100,000 screens per day, a five-fold increase in productivity.

Nanoworms Make Tumors Squirm

Nano-scale worms made out of iron oxide (rust) may be the next big breakthrough in cancer treatment. Erkki Ruoslahti, M.D., Ph.D., along with collaborators at the University of California, San Diego and the Massachusetts Institute of Technology, has shown that iron oxide nanoworms can bind to tumors when coated with tumor-homing peptides. The team is now attempting to design nanoparticles that will seek out tumors in the body, send a diagnostic signal and release a drug at the site of the tumor in a controlled manner.

What's in Fashion: Designer Drugs to Block Breast Cancer

Gregory Roth, Ph.D., and colleagues have determined that a biologically active molecule called a chemokine promotes the spread of tumors, particularly in breast cancer. Dr. Roth believes that compounds that block the chemokine may be potential cancer therapies. However, existing small molecules that bind to chemokines only bind weakly, making them poor drug candidates. Dr. Roth and a team of Burnham chemists are working to custom-design molecules that bind tightly to the chemokine, hoping to block its activity and stop the spread of tumors.

Choking Out Cancer

Ze'ev Ronai, Ph.D. is trying to kill off cancer by choking it. When tumors are deprived of oxygen, they activate a transcription factor called HIF-1a that helps the tumor compensate and survive. Inhibiting HIF-1a has been hypothesized to be a means of defeating cancer, as tumors eventually experience oxygen deprivation due to insufficient blood flow to the tumor. Dr. Ronai's laboratory has demonstrated proof of this concept by inhibiting PHD3, a regulator of HIF-1a. Binding of short protein fragments to PHD3 results in HIF-1a degradation and halts growth of metastatic tumors in mice. Dr. Ronai's team is now investigating how small molecule compounds might accomplish the same thing.


Contact: Josh Baxt
Burnham Institute

Related biology news :

1. Burnham researchers turn cancer friend into cancer foe
2. Burnham researcher awarded $8 million grant
Post Your Comments:
(Date:10/29/2015)... 29, 2015  The J. Craig Venter Institute (JCVI) ... Synthesis and Biosecurity: Lessons Learned and Options for the ... and Human Services guidance for synthetic biology providers has ... --> --> Synthetic biology ... potential to pose unique biosecurity threats. It now is ...
(Date:10/29/2015)... OXFORD, Connecticut , October 29, 2015 /PRNewswire/ ... "Company"), a biometric authentication company focused on the ... Wocket® smart wallet announces that StackCommerce, a leading ... will be featuring the Wocket® smart wallet on ... NXTD ) ("NXT-ID" or the "Company"), a ...
(Date:10/27/2015)... Oct. 27, 2015 Synaptics Inc. (NASDAQ: SYNA ... that Google has adopted the Synaptics ® ClearPad ... to power its newest flagship smartphones, the Nexus 5X ... --> --> Synaptics ... provide strategic collaboration in the joint development of next ...
Breaking Biology News(10 mins):
(Date:11/30/2015)... and PETACH TIKVAH, Israel , Nov. 30, ... BCLI ), a leading developer of adult stem cell technologies ... Cell Therapeutics Ltd., has been awarded an additional grant of ... the Chief Scientist (OCS). This grant, the second this year, ... activities to approximately $1.8 million (approximately NIS7 million).  ...
(Date:11/27/2015)... PA (PRWEB) , ... November 27, 2015 , ... ... Technical Program that includes over 2,000 technical presentations offered in symposia, oral ... chemistry and applied spectroscopy, covers a wide range of applications such as, but ...
(Date:11/26/2015)... November 26, 2015 --> ... specializing in imaging technologies, announced today that it has received ... of the Horizon 2020 European Union Framework Programme for Research ... clinical trial in breast cancer. , --> ... --> --> The study aims ...
(Date:11/25/2015)... 2 nouvelles études permettent d , ... les souches bactériennes retrouvées dans la plaque dentaire ... . Ces recherches  ouvrent une nouvelle voie ... de l,un des problèmes de santé les plus ... --> 2 nouvelles études permettent d , ...
Breaking Biology Technology: